商务合作
动脉网APP
可切换为仅中文
MSD has called a halt to three trials of BTK inhibitor nemtabrutinib – added to its pipeline through its $2.7 billion acquisition of ArQule – after initial results suggested that the drug's benefits are unlikely to outweigh its risks.
默沙东已叫停BTK抑制剂nemtabrutinib的三项临床试验,该药物是通过其以27亿美元收购ArQule公司而纳入其产品管线的;初步结果显示,该药的获益可能无法超过其风险。
In a statement, MSD – known as Merck & Co in the US and Canada – said that it is discontinuing the clinical development programme for nemtabrutinib (MK-1026), a non-covalent BTK inhibitor that was being tested for leukaemia and other haematological malignancies.
默沙东(在美国和加拿大称为默克公司)在一份声明中表示,正在终止非共价BTK抑制剂nemtabrutinib(MK-1026)的临床开发计划,该药物此前正在接受针对白血病及其他血液系统恶性肿瘤的测试。
The decision affects the phase 3 BELLWAVE programme and was prompted by data from
该决定影响三期BELLWAVE项目,并由以下数据引发
BELLWAVE-011, which was comparing MSD's drug to Pfizer's Imbruvica (ibrutinib) and AstraZeneca's Calquence (acalabrutinib) – both covalent BTK inhibitors – as a first-line treatment for patients with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL).
BELLWAVE-011 研究将默沙东的药物与辉瑞的 Imbruvica(伊布替尼)和阿斯利康的 Calquence(阿卡替尼)进行比较,后两者均为共价 BTK 抑制剂,该研究旨在评估它们作为慢性淋巴细胞白血病(CLL)或小淋巴细胞淋巴瘤(SLL)患者一线治疗的效果。
After a review confirmed a safety signal in the trial, MSD decided to also discontinue two other phase 3 trials – BELLWAVE-008 and BELLWAVE-010 – which were testing the drug, respectively, as a monotherapy in patients with previously untreated CLL/SLL without TP53 aberrations and as a combination regimen in relapsed/refractory CLL/SLL..
在审查确认试验中存在安全性信号后,默沙东决定也终止另外两项III期临床试验——BELLWAVE-008和BELLWAVE-010。这两项试验分别评估该药物作为单药疗法用于既往未经治疗且无TP53异常的慢性淋巴细胞白血病/小淋巴细胞淋巴瘤(CLL/SLL)患者,以及作为联合方案用于复发/难治性CLL/SLL患者。
'Following careful analyses of the data from BELLWAVE-011, the decision has been made to discontinue development of nemtabrutinib across the entire clinical programme,' said Dr Marjorie Green, head of global oncology clinical development at Merck Research Laboratories. 'We continue to pursue solutions for patients with haematologic malignancies.'.
默克研究实验室全球肿瘤临床开发负责人 Marjorie Green 博士表示:“在对 BELLWAVE-011 研究数据进行仔细分析后,我们决定终止 nemtabrutinib 在整个临床项目中的开发。我们将继续为血液系统恶性肿瘤患者寻求治疗方案。”
It's a disappointing end for a drug candidate that had been held up by MSD as a future blockbuster when it
对于一个曾被默沙东寄予厚望、视为未来重磅炸弹的药物候选者来说,这是一个令人失望的结局。
bought ArQule
收购ArQule
in 2019, offering activity against both wild-type BTK and mutant forms of the enzyme that are associated with resistance to other BTK inhibitors.
在2019年,提供针对野生型BTK以及与对其他BTK抑制剂耐药性相关的突变形式的酶的活性。
Since then, prospects for the programme have diminished, with MSD taking multiple charges in its accounting as a result of developmental delays and increased competition in the BTK inhibitor category, particularly from other non-covalent entrants like Eli Lilly's Jaypirca (pirtobrutinib).
自那时以来,该计划的前景已趋黯淡,默沙东因研发延误以及BTK抑制剂类别竞争加剧(尤其是来自礼来公司Jaypirca(pirtobrutinib)等其他非共价抑制剂的竞争),在财务核算中多次计提费用。
Jaypirca was the first non-covalent or reversible BTK inhibitor to be approved by the FDA, and has grown rapidly since its first launch in 2023, with sales growing 63% to $585 million in the first nine months of 2026.
Jaypirca 是美国食品药品监督管理局(FDA)批准的首个非共价或可逆性 BTK 抑制剂,自 2023 年首次上市以来迅速增长,2026 年前九个月的销售额增长了 63%,达到 5.85 亿美元。
Jaypirca's label was extended last month to include first-line treatment of CLL/SLL, but the drug still lags behind BeOne Medicine's masrket-leading covalent inhibitor Brukinsa (zanubrutinib), as well as Calquence and Imbruvica, as it tends to be saved for use when resistance to BTK drugs has developed..
Jaypirca的适应症标签上月已扩展,涵盖慢性淋巴细胞白血病/小淋巴细胞淋巴瘤(CLL/SLL)的一线治疗,但该药仍落后于百济神州的市场领先共价抑制剂Brukinsa(泽布替尼),以及Calquence和Imbruvica,因为它通常被保留用于对BTK抑制剂产生耐药性的情况。